UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation

Genome biology, 2014-07, Vol.15 (7), p.408-408, Article 408

2014

Volltextzugriff (PDF)

Drug development for hepatocellular carcinoma

The lancet oncology, 2023-12, Vol.24 (12), p.1292-1294

2023

Volltextzugriff (PDF)

The combination of ALBI and AFP response: A small step forward in HCC

Liver international, 2023-02, Vol.43 (2), p.271-273

2023

Volltextzugriff (PDF)

Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma

Journal of hepatology, 2024-06, Vol.80 (6), p.e282-e283

2024

Volltextzugriff (PDF)

Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond

Current oncology (Toronto), 2022-08, Vol.29 (8), p.5489-5507

2022

Volltextzugriff (PDF)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Clinical and molecular hepatology, 2023-10, Vol.29 (4), p.909-923

2023

Volltextzugriff (PDF)

Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma

Cancers, 2022-03, Vol.14 (6), p.1526

2022

Volltextzugriff (PDF)

The prime time for management of hepatocellular carcinoma in Hong Kong

Clinical and molecular hepatology, 2023-04, Vol.29 (2), p.345-348

2023

Volltextzugriff (PDF)

Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment

Journal of hepatology, 2024-08, Vol.81 (2), p.258-264

2024

Volltextzugriff (PDF)

Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study

Liver international, 2024-08, Vol.44 (8), p.1961-1970

2024

Volltextzugriff (PDF)

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Investigational new drugs, 2021-10, Vol.39 (5), p.1375-1382

2021

Volltextzugriff (PDF)

Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma

Expert opinion on emerging drugs, 2021-01, Vol.26 (1), p.39-52

2021

Volltextzugriff (PDF)

Bioinformatics analysis of circulating cell-free DNA sequencing data

Clinical biochemistry, 2015-10, Vol.48 (15), p.962-975

2015

Volltextzugriff (PDF)

Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk

Clinical lung cancer, 2024-07

2024

Volltextzugriff (PDF)

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC

Lung cancer (Amsterdam, Netherlands), 2024-07, Vol.193, p.107856, Article 107856

2024

Volltextzugriff (PDF)

Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients

Journal of gastroenterology, 2014-10, Vol.49 (10), p.1414-1420

2014

Volltextzugriff (PDF)

Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants

Human molecular genetics, 2012-12, Vol.21 (23), p.5209-5221

2012

Volltextzugriff (PDF)

A network approach to exploring the functional basis of gene-gene epistatic interactions in disease susceptibility

Bioinformatics, 2018-05, Vol.34 (10), p.1741-1749

2018

Volltextzugriff (PDF)

Risks and impacts of thromboembolism in patients with pancreatic cancer

Hong Kong Medical Journal, 2023-10, Vol.29 (5), p.396-403

2023

Volltextzugriff (PDF)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Kliničeskij razbor v obŝej medicine (Online), 2024-07, Vol.5 (7), p.24-36

2024

Volltextzugriff (PDF)

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease

JTO clinical and research reports, 2024-04, Vol.5 (4), p.100648-100648, Article 100648

2024

Volltextzugriff (PDF)

Systemic treatment of pancreatic neuroendocrine tumors

Surgical practice, 2019-05, Vol.23 (2), p.48-58

2019

Volltextzugriff (PDF)

Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study

Hong Kong Medical Journal, 2022-12, Vol.28 (6), p.438

2022

Volltextzugriff (PDF)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma

Journal of liver cancer, 2023-09, Vol.23 (2), p.262-271

2023

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(76)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation

Drug development for hepatocellular carcinoma

The combination of ALBI and AFP response: A small step forward in HCC

Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma

Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma

The prime time for management of hepatocellular carcinoma in Hong Kong

Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment

Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma

Bioinformatics analysis of circulating cell-free DNA sequencing data

Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC

Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients

Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants

A network approach to exploring the functional basis of gene-gene epistatic interactions in disease susceptibility

Risks and impacts of thromboembolism in patients with pancreatic cancer

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease

Systemic treatment of pancreatic neuroendocrine tumors

Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma

Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries

Suchergebnisse filtern